{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T17:38:27Z","timestamp":1783445907780,"version":"3.55.0"},"reference-count":138,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2006,9,1]],"date-time":"2006-09-01T00:00:00Z","timestamp":1157068800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Seminars in Pediatric Neurology"],"published-print":{"date-parts":[[2006,9]]},"DOI":"10.1016\/j.spen.2006.08.008","type":"journal-article","created":{"date-parts":[[2006,11,14]],"date-time":"2006-11-14T15:46:46Z","timestamp":1163519206000},"page":"186-197","source":"Crossref","is-referenced-by-count":83,"title":["Iron: A New Target for Pharmacological Intervention in Neurodegenerative Diseases"],"prefix":"10.1016","volume":"13","author":[{"given":"Megan","family":"Whitnall","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Des R.","family":"Richardson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.spen.2006.08.008_bib1","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1196\/annals.1306.022","article-title":"Hereditary causes of disturbed iron homeostasis in the central nervous system","volume":"1012","author":"Ponka","year":"2004","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.spen.2006.08.008_bib2","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1023\/A:1020718718550","article-title":"Brain iron uptake and homeostatic mechanisms: An overview","volume":"16","author":"Burdo","year":"2003","journal-title":"Biometals"},{"key":"10.1016\/j.spen.2006.08.008_bib3","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/0006-8993(93)90341-J","article-title":"Iron induced oxidative stress and mitochondrial dysfunction: Relevance to Parkinson\u2019s disease","volume":"627","author":"Harley","year":"1993","journal-title":"Brain Res"},{"key":"10.1016\/j.spen.2006.08.008_bib4","doi-asserted-by":"crossref","first-page":"115","DOI":"10.2165\/00002512-199914020-00004","article-title":"The role of iron in neurodegeneration: Prospects for pharmacotherapy of Parkinson\u2019s disease","volume":"14","author":"Jellinger","year":"1999","journal-title":"Drugs Aging"},{"key":"10.1016\/j.spen.2006.08.008_bib5","first-page":"743","article-title":"Iron involvement in neural damage and microgliosis in models of neurodegenerative diseases","volume":"46","author":"Shoham","year":"2000","journal-title":"Cell Mol Biol"},{"key":"10.1016\/j.spen.2006.08.008_bib6","series-title":"Iron Transport in the Central Nervous System. Molecular and Cellular Iron Transport","first-page":"487","author":"Burdo","year":"2002"},{"key":"10.1016\/j.spen.2006.08.008_bib7","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1038\/nrn1537","article-title":"Iron, brain ageing and neurodegenerative disorders","volume":"5","author":"Zecca","year":"2004","journal-title":"Nat Rev Neurosci"},{"key":"10.1016\/j.spen.2006.08.008_bib8","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1038\/sj.bjp.0706416","article-title":"The crucial role of metal ions in neurodegeneration: The basis for a promising therapeutic strategy","volume":"146","author":"Gaeta","year":"2005","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.spen.2006.08.008_bib9","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1093\/hmg\/ddi461","article-title":"Mitochondrial iron detoxification is a primary function of frataxin that limits oxidative damage and preserves cell longevity","volume":"15","author":"Gakh","year":"2006","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.spen.2006.08.008_bib10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0304-4157(96)00014-7","article-title":"The molecular mechanisms of the metabolism and transport of iron in normal and neoplastic cells","volume":"1331","author":"Richardson","year":"1997","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.spen.2006.08.008_bib11","first-page":"35","article-title":"Function and regulation of transferrin and ferritin","volume":"35","author":"Ponka","year":"1998","journal-title":"Semin Hematol"},{"key":"10.1016\/j.spen.2006.08.008_bib12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0098-2997(81)90003-0","article-title":"Transferrin biochemistry, physiology, and clinical significance","volume":"4","author":"Morgan","year":"1981","journal-title":"Mol Aspects Med"},{"key":"10.1016\/j.spen.2006.08.008_bib13","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1038\/ng0897-383","article-title":"Microcytic anaemia mice have a mutation in Nramp2, a candidate iron transporter gene","volume":"16","author":"Fleming","year":"1997","journal-title":"Nat Genet"},{"key":"10.1016\/j.spen.2006.08.008_bib14","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1002\/jcp.1041610119","article-title":"Two saturable mechanisms of iron uptake from transferrin in human melanoma cells: The effect of transferrin concentration, chelators, and metabolic probes on transferrin and iron uptake","volume":"161","author":"Richardson","year":"1994","journal-title":"J Cell Physiol"},{"key":"10.1016\/j.spen.2006.08.008_bib15","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/0165-3806(90)90103-6","article-title":"Developmental changes in transferrin and iron uptake by the brain in the rat","volume":"55","author":"Taylor","year":"1990","journal-title":"Brain Res Dev Brain Res"},{"key":"10.1016\/j.spen.2006.08.008_bib16","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1242\/jcs.104.2.521","article-title":"Receptor-mediated endocytosis of transferrin at the blood-brain barrier","volume":"104","author":"Roberts","year":"1993","journal-title":"J Cell Sci"},{"key":"10.1016\/j.spen.2006.08.008_bib17","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/0006-8993(96)88505-2","article-title":"Coincident expression and distribution of melanotransferrin and transferrin receptor in human brain capillary endothelium","volume":"712","author":"Rothenberger","year":"1996","journal-title":"Brain Res"},{"key":"10.1016\/j.spen.2006.08.008_bib18","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1046\/j.1471-4159.2002.01201.x","article-title":"High transcytosis of melanotransferrin (P97) across the blood-brain barrier","volume":"803","author":"Demeule","year":"2002","journal-title":"J Neurochem"},{"key":"10.1016\/j.spen.2006.08.008_bib19","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/S0014-5793(00)02079-2","article-title":"The membrane-bound transferrin homologue melanotransferrin: Roles other than iron transport?","volume":"483","author":"Sekyere","year":"2000","journal-title":"FEBS Lett"},{"key":"10.1016\/j.spen.2006.08.008_bib20","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.bbadis.2004.06.002","article-title":"The transferrin homologue, melanotransferrin (p97), is rapidly catabolized by the liver of the rat and does not effectively donate iron to the brain","volume":"1690","author":"Richardson","year":"2004","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.spen.2006.08.008_bib21","doi-asserted-by":"crossref","first-page":"2599","DOI":"10.1182\/blood-2005-10-4174","article-title":"Role of melanotransferrin in iron metabolism: Studies using targeted gene disruption in vivo","volume":"107","author":"Sekyere","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.spen.2006.08.008_bib22","series-title":"Carcinogenesis","article-title":"The function of melanotransferrin: A role in melanoma cell proliferation and tumorigenesis","author":"Dunn","year":"2006"},{"key":"10.1016\/j.spen.2006.08.008_bib23","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1182\/blood-2004-10-3856","article-title":"Iron trafficking in the mitochondrion: Novel pathways revealed by disease","volume":"105","author":"Napier","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.spen.2006.08.008_bib24","doi-asserted-by":"crossref","first-page":"3477","DOI":"10.1182\/blood.V87.8.3477.bloodjournal8783477","article-title":"Distribution of iron in reticulocytes after inhibition of heme synthesis with succinylacetone: Examination of the intermediates involved in iron metabolism","volume":"87","author":"Richardson","year":"1996","journal-title":"Blood"},{"key":"10.1016\/j.spen.2006.08.008_bib25","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1111\/j.1471-4159.1991.tb06358.x","article-title":"Iron-melanin interaction and lipid peroxidation: Implications for Parkinson\u2019s disease","volume":"57","author":"Ben-Shachar","year":"1991","journal-title":"J Neurochem"},{"key":"10.1016\/j.spen.2006.08.008_bib26","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/S0006-2952(03)00293-4","article-title":"Iron-binding characteristics of neuromelanin of the human substantia nigra","volume":"66","author":"Double","year":"2003","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.spen.2006.08.008_bib27","first-page":"333","article-title":"The significance of neuromelanin in Parkinson\u2019s disease","volume":"12","author":"Double","year":"1999","journal-title":"Drug News Dev"},{"key":"10.1016\/j.spen.2006.08.008_bib28","doi-asserted-by":"crossref","first-page":"8175","DOI":"10.1073\/pnas.93.16.8175","article-title":"Molecular control of vertebrate iron metabolism: mRNA-based regulatory circuits operated by iron, nitric oxide, and oxidative stress","volume":"93","author":"Hentze","year":"1996","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.spen.2006.08.008_bib29","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1016\/S0006-2952(99)00017-9","article-title":"Therapy by taking away: the case of iron","volume":"57","author":"Polla","year":"1999","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.spen.2006.08.008_bib30","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1038\/nrd1330","article-title":"Neurodegenerative diseases and oxidative stress","volume":"3","author":"Barnham","year":"2004","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.spen.2006.08.008_bib31","first-page":"148","article-title":"The absorption and excretion of Fe following oral and intravenous administration","volume":"94","author":"McCance","year":"1938","journal-title":"J Phys"},{"key":"10.1016\/j.spen.2006.08.008_bib32","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1172\/JCI17742","article-title":"Huntingtin in health and disease","volume":"111","author":"Young","year":"2003","journal-title":"J Clin Invest"},{"key":"10.1016\/j.spen.2006.08.008_bib33","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1590\/S0004-282X2006000100002","article-title":"Clinical presentation of juvenile Huntington disease","volume":"64","author":"Ruocco","year":"2006","journal-title":"Ar Qneuropsiquiatr"},{"key":"10.1016\/j.spen.2006.08.008_bib34","doi-asserted-by":"crossref","first-page":"2435","DOI":"10.1097\/00001756-199908200-00001","article-title":"Caspase activation during apoptotic cell death induced by expanded polyglutamine in N2a cells","volume":"10","author":"Wang","year":"1999","journal-title":"Neuroreport"},{"key":"10.1016\/j.spen.2006.08.008_bib35","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.cell.2004.06.018","article-title":"Huntingtin controls neurotrophic support and survival of neurons by enhancing BDNF vesicular transport along microtubules","volume":"118","author":"Gauthier","year":"2004","journal-title":"Cell"},{"key":"10.1016\/j.spen.2006.08.008_bib36","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/S0896-6273(02)00872-3","article-title":"Polyglutamine pathogenesis: Emergence of unifying mechanisms for Huntington\u2019s disease and related disorders","volume":"35","author":"Ross","year":"2002","journal-title":"Neuron"},{"key":"10.1016\/j.spen.2006.08.008_bib37","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/S0896-6273(00)81104-6","article-title":"Expanding our understanding of polyglutamine diseases through mouse models","volume":"24","author":"Lin","year":"1999","journal-title":"Neuron"},{"key":"10.1016\/j.spen.2006.08.008_bib38","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/0166-2236(93)90117-5","article-title":"Do defects in mitochondrial energy metabolism underlie the pathology of neurodegenerative diseases?","volume":"16","author":"Beal","year":"1993","journal-title":"Trends Neurosci"},{"key":"10.1016\/j.spen.2006.08.008_bib39","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1111\/j.1750-3639.1999.tb00216.x","article-title":"Oxidative stress in Huntington\u2019s disease","volume":"9","author":"Browne","year":"1999","journal-title":"Brain Pathol"},{"key":"10.1016\/j.spen.2006.08.008_bib40","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.bbrc.2006.01.136","article-title":"Oxidative stress promotes mutant huntingtin aggregation and mutant huntingtin-dependent cell death by mimicking proteasomal malfunction","volume":"342","author":"Goswami","year":"2006","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.spen.2006.08.008_bib41","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1093\/brain\/114.4.1953","article-title":"Alterations in the levels of iron, ferritin and other trace metals in Parkinson\u2019s disease and other neurodegenerative diseases affecting the basal ganglia","volume":"114","author":"Dexter","year":"1991","journal-title":"Brain"},{"key":"10.1016\/j.spen.2006.08.008_bib42","doi-asserted-by":"crossref","first-page":"2789","DOI":"10.1093\/hmg\/9.19.2789","article-title":"Huntingtin: An iron-regulated protein essential for normal nuclear and perinuclear organelles","volume":"9","author":"Hilditch-Maguire","year":"2000","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.spen.2006.08.008_bib43","doi-asserted-by":"crossref","first-page":"7317","DOI":"10.1073\/pnas.122249699","article-title":"The galvanization of beta-amyloid in Alzheimer\u2019s disease","volume":"99","author":"Bush","year":"2002","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.spen.2006.08.008_bib44","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1196\/annals.1306.015","article-title":"Oxidative stress and redox-active iron in Alzheimer\u2019s disease","volume":"1012","author":"Honda","year":"2004","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.spen.2006.08.008_bib45","doi-asserted-by":"crossref","first-page":"20978","DOI":"10.1074\/jbc.M500526200","article-title":"Ribosomal RNA in Alzheimer disease is oxidized by bound redox-active iron","volume":"280","author":"Honda","year":"2005","journal-title":"J Biol Chem"},{"key":"10.1016\/j.spen.2006.08.008_bib46","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1159\/000065701","article-title":"Brain iron metabolism and neurodegenerative disorders","volume":"24","author":"Sipe","year":"2002","journal-title":"Dev Neurosci"},{"key":"10.1016\/j.spen.2006.08.008_bib47","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1002\/jnr.490310214","article-title":"Regional distribution of iron and iron-regulatory proteins in the brain in aging and Alzheimer\u2019s disease","volume":"31","author":"Connor","year":"1992","journal-title":"J Neurosci Res"},{"key":"10.1016\/j.spen.2006.08.008_bib48","doi-asserted-by":"crossref","first-page":"9866","DOI":"10.1073\/pnas.94.18.9866","article-title":"Iron accumulation in Alzheimer disease is a source of redox-generated free radicals","volume":"94","author":"Smith","year":"1997","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.spen.2006.08.008_bib49","first-page":"309","article-title":"Role of free radicals and metal ions in the pathogenesis of Alzheimer\u2019s disease","volume":"36","author":"Atwood","year":"1999","journal-title":"Met Ions Biol Syst"},{"key":"10.1016\/j.spen.2006.08.008_bib50","doi-asserted-by":"crossref","first-page":"S226","DOI":"10.1016\/S0197-4580(00)83347-3","article-title":"B-Amyloid helps to protect neurons from oxidative stress","volume":"21","author":"Bishop","year":"2000","journal-title":"Neurobiol Aging"},{"key":"10.1016\/j.spen.2006.08.008_bib51","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/S0891-5849(00)00494-9","article-title":"Redox-active iron mediates amyloid-beta toxicity","volume":"30","author":"Rottkamp","year":"2001","journal-title":"Free Radic Biol Med"},{"key":"10.1016\/j.spen.2006.08.008_bib52","doi-asserted-by":"crossref","first-page":"45518","DOI":"10.1074\/jbc.M207435200","article-title":"An iron-responsive element type II in the 5\u2032-untranslated region of the Alzheimer\u2019s amyloid precursor protein transcript","volume":"277","author":"Rogers","year":"2002","journal-title":"J Biol Chem"},{"key":"10.1016\/j.spen.2006.08.008_bib53","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1301\/nr.2003.sept.311-313","article-title":"Iron and Parkinson\u2019s disease: Chelators to the rescue?","volume":"61","author":"Levenson","year":"2003","journal-title":"Nutr Rev"},{"key":"10.1016\/j.spen.2006.08.008_bib54","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1007\/s00702-004-0212-1","article-title":"Gene expression profiling of parkinsonian substantia nigra pars compacta; alterations in ubiquitin-proteasome, heat shock protein, iron and oxidative stress regulated proteins, cell adhesion\/cellular matrix and vesicle trafficking genes","volume":"111","author":"Grunblatt","year":"2004","journal-title":"J Neural Transm"},{"key":"10.1016\/j.spen.2006.08.008_bib55","doi-asserted-by":"crossref","first-page":"729","DOI":"10.2165\/00023210-200317100-00004","article-title":"Neuroprotective strategies in Parkinson\u2019s disease: An update on progress","volume":"17","author":"Mandel","year":"2003","journal-title":"CNS Drugs"},{"key":"10.1016\/j.spen.2006.08.008_bib56","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1196\/annals.1306.025","article-title":"Ironing iron out in Parkinson\u2019s disease and other neurodegenerative diseases with iron chelators: A lesson from 6-hydroxydopamine and iron chelators, desferal and VK-28","volume":"1012","author":"Youdim","year":"2004","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.spen.2006.08.008_bib57","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1016\/S0896-6273(03)00126-0","article-title":"Genetic or pharmacological iron chelation prevents MPTP-induced neurotoxicity in vivo: A novel therapy for Parkinson\u2019s disease","volume":"37","author":"Kaur","year":"2003","journal-title":"Neuron"},{"key":"10.1016\/j.spen.2006.08.008_bib58","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1212\/WNL.45.6.1138","article-title":"Increased iron-related MRI contrast in the substantia nigra in Parkinson\u2019s disease","volume":"45","author":"Gorell","year":"1995","journal-title":"Neurology"},{"key":"10.1016\/j.spen.2006.08.008_bib59","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1001\/archneur.1995.00540300057013","article-title":"Magnetic resonance imaging evidence of decreased putamenal iron content in idiopathic Parkinson\u2019s disease","volume":"52","author":"Ryvlin","year":"1995","journal-title":"Arch Neurol"},{"key":"10.1016\/j.spen.2006.08.008_bib60","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0730-725X(96)00234-2","article-title":"MR evaluation of age-related increase of brain iron in young adults and older normal males","volume":"15","author":"Bartzokis","year":"1997","journal-title":"Magn Reson Imaging"},{"key":"10.1016\/j.spen.2006.08.008_bib61","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1111\/j.1471-4159.1989.tb09150.x","article-title":"Transition metals, ferritin, glutathione, and ascorbic acid in parkinsonian brains","volume":"52","author":"Riederer","year":"1989","journal-title":"J Neurochem"},{"key":"10.1016\/j.spen.2006.08.008_bib62","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1016\/S0006-2952(02)01174-7","article-title":"Glutathione, iron and Parkinson\u2019s disease","volume":"64","author":"Bharath","year":"2002","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.spen.2006.08.008_bib63","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1042\/bst0300559","article-title":"Aggregation and neurotoxicity of alpha-synuclein and related peptides","volume":"30","author":"el-Agnaf","year":"2002","journal-title":"Biochem Soc Trans"},{"key":"10.1016\/j.spen.2006.08.008_bib64","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1046\/j.1471-4159.2002.01118.x","article-title":"Lack of up-regulation of ferritin is associated with sustained iron regulatory protein-1 binding activity in the substantia nigra of patients with Parkinson\u2019s disease","volume":"83","author":"Faucheux","year":"2002","journal-title":"J Neurochem"},{"key":"10.1016\/j.spen.2006.08.008_bib65","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1002\/jnr.10463","article-title":"Mouse brains deficient in H-ferritin have normal iron concentration but a protein profile of iron deficiency and increased evidence of oxidative stress","volume":"71","author":"Thompson","year":"2003","journal-title":"J Neurosci Res"},{"key":"10.1016\/j.spen.2006.08.008_bib66","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1046\/j.1471-4159.2003.01923.x","article-title":"Neuromelanin associated redox-active iron is increased in the substantia nigra of patients with Parkinson\u2019s disease","volume":"86","author":"Faucheux","year":"2003","journal-title":"J Neurochem"},{"key":"10.1016\/j.spen.2006.08.008_bib67","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/S0925-4439(99)00116-7","article-title":"Q-band EPR investigations of neuromelanin in control and Parkinson\u2019s disease patients","volume":"1500","author":"Lopiano","year":"2000","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.spen.2006.08.008_bib68","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1126\/science.271.5254.1423","article-title":"Friedreich\u2019s ataxia: Autosomal recessive disease caused by an intronic GAA triplet repeat expansion","volume":"271","author":"Campuzano","year":"1996","journal-title":"Science"},{"key":"10.1016\/j.spen.2006.08.008_bib69","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1038\/ng0897-345","article-title":"Studies of human, mouse and yeast homologues indicate a mitochondrial function for frataxin","volume":"16","author":"Koutnikova","year":"1997","journal-title":"Nat Genet"},{"key":"10.1016\/j.spen.2006.08.008_bib70","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1212\/WNL.47.5.1260","article-title":"Age of onset, sex, and cardiomyopathy as predictors of disability and survival in Friedreich\u2019s disease: A retrospective study on 119 patients","volume":"47","author":"De Michele","year":"1996","journal-title":"Neurology"},{"key":"10.1016\/j.spen.2006.08.008_bib71","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1093\/brain\/104.3.589","article-title":"Friedreich\u2019s ataxia: A clinical and genetic study of 90 families with an analysis of early diagnostic criteria and intrafamilial clustering of clinical features","volume":"104","author":"Harding","year":"1981","journal-title":"Brain"},{"key":"10.1016\/j.spen.2006.08.008_bib72","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1056\/NEJM199610173351601","article-title":"Clinical and genetic abnormalities in patients with Friedreich\u2019s ataxia","volume":"335","author":"Durr","year":"1996","journal-title":"N Engl J Med"},{"key":"10.1016\/j.spen.2006.08.008_bib73","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1093\/hmg\/9.8.1219","article-title":"Inactivation of the Friedreich ataxia mouse gene leads to early embryonic lethality without iron accumulation","volume":"9","author":"Cossee","year":"2000","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.spen.2006.08.008_bib74","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1093\/hmg\/9.2.275","article-title":"Clinical, biochemical and molecular genetic correlations in Friedreich\u2019s ataxia","volume":"9","author":"Bradley","year":"2000","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.spen.2006.08.008_bib75","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/S0887-8994(03)00004-3","article-title":"Friedreich\u2019s ataxia","volume":"28","author":"Alper","year":"2003","journal-title":"Pediatr Neurol"},{"key":"10.1016\/j.spen.2006.08.008_bib76","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1080\/10715760290021324","article-title":"Mitochondrial dysfunction in Friedreich\u2019s ataxia: From pathogenesis to treatment perspectives","volume":"36","author":"Lodi","year":"2002","journal-title":"Free Radic Res"},{"key":"10.1016\/j.spen.2006.08.008_bib77","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.ymgme.2005.04.010","article-title":"Molecular and functional characterization of a human frataxin mutation found in hypertrophic cardiomyopathy","volume":"85","author":"Van Driest","year":"2005","journal-title":"Mol Genet Metab"},{"key":"10.1016\/j.spen.2006.08.008_bib78","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1126\/science.276.5319.1709","article-title":"Regulation of mitochondrial iron accumulation by Yfh1p, a putative homolog of frataxin","volume":"276","author":"Babcock","year":"1997","journal-title":"Science"},{"key":"10.1016\/j.spen.2006.08.008_bib79","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1093\/hmg\/6.11.1771","article-title":"Frataxin is reduced in Friedreich ataxia patients and is associated with mitochondrial membranes","volume":"6","author":"Campuzano","year":"1997","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.spen.2006.08.008_bib80","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/S0014-5793(97)00734-5","article-title":"Deletion of the yeast homologue of the human gene associated with Friedreich\u2019s ataxia elicits iron accumulation in mitochondria","volume":"411","author":"Foury","year":"1997","journal-title":"FEBS Lett"},{"key":"10.1016\/j.spen.2006.08.008_bib81","doi-asserted-by":"crossref","first-page":"4497","DOI":"10.1074\/jbc.274.8.4497","article-title":"The yeast frataxin homologue mediates mitochondrial iron efflux. Evidence for a mitochondrial iron cycle","volume":"274","author":"Radisky","year":"1999","journal-title":"J Biol Chem"},{"key":"10.1016\/j.spen.2006.08.008_bib82","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1093\/hmg\/8.3.425","article-title":"The Friedreich\u2019s ataxia mutation confers cellular sensitivity to oxidant stress which is rescued by chelators of iron and calcium and inhibitors of apoptosis","volume":"8","author":"Wong","year":"1999","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.spen.2006.08.008_bib83","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/ng1097-215","article-title":"Aconitase and mitochondrial iron-sulphur protein deficiency in Friedreich ataxia","volume":"17","author":"Rotig","year":"1997","journal-title":"Nat Genet"},{"key":"10.1016\/j.spen.2006.08.008_bib84","series-title":"Handbook of Cerebellar Diseases","first-page":"453","author":"Lamarche","year":"1993"},{"key":"10.1016\/j.spen.2006.08.008_bib85","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/84818","article-title":"Mouse models for Friedreich ataxia exhibit cardiomyopathy, sensory nerve defect and Fe-S enzyme deficiency followed by intramitochondrial iron deposits","volume":"27","author":"Puccio","year":"2001","journal-title":"Nat Genet"},{"key":"10.1016\/j.spen.2006.08.008_bib86","doi-asserted-by":"crossref","first-page":"38589","DOI":"10.1074\/jbc.M206711200","article-title":"The ferroxidase activity of yeast frataxin","volume":"277","author":"Park","year":"2002","journal-title":"J Biol Chem"},{"key":"10.1016\/j.spen.2006.08.008_bib87","doi-asserted-by":"crossref","first-page":"31340","DOI":"10.1074\/jbc.M303158200","article-title":"Yeast frataxin sequentially chaperones and stores iron by coupling protein assembly with iron oxidation","volume":"278","author":"Park","year":"2003","journal-title":"J Biol Chem"},{"key":"10.1016\/j.spen.2006.08.008_bib88","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1021\/bi048459j","article-title":"Assembly of human frataxin is a mechanism for detoxifying redox-active iron","volume":"44","author":"O\u2019Neill","year":"2005","journal-title":"Biochemistry"},{"key":"10.1016\/j.spen.2006.08.008_bib89","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/S0891-5849(02)00772-4","article-title":"Molecular bases of cellular iron toxicity","volume":"32","author":"Eaton","year":"2002","journal-title":"Free Radic Biol Med"},{"key":"10.1016\/j.spen.2006.08.008_bib90","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1093\/hmg\/ddh114","article-title":"Idebenone delays the onset of cardiac functional alteration without correction of Fe-S enzymes deficit in a mouse model for Friedreich ataxia","volume":"13","author":"Seznec","year":"2004","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.spen.2006.08.008_bib91","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1093\/hmg\/ddi042","article-title":"Friedreich ataxia: The oxidative stress paradox","volume":"14","author":"Seznec","year":"2005","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.spen.2006.08.008_bib92","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1212\/WNL.55.11.1719","article-title":"Oxidative stress in patients with Friedreich ataxia","volume":"55","author":"Schulz","year":"2000","journal-title":"Neurology"},{"key":"10.1016\/j.spen.2006.08.008_bib93","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1023\/B:NERE.0000014826.00881.c3","article-title":"Role of oxidative damage in Friedreich\u2019s ataxia","volume":"29","author":"Bradley","year":"2004","journal-title":"Neurochem Res"},{"key":"10.1016\/j.spen.2006.08.008_bib94","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1002\/ajh.10348","article-title":"Iron chelators for the treatment of iron overload disease: Relationship between structure, redox activity, and toxicity","volume":"73","author":"Chaston","year":"2003","journal-title":"Am J Hematol"},{"key":"10.1016\/j.spen.2006.08.008_bib95","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1124\/pr.57.4.2","article-title":"The evolution of iron chelators for the treatment of iron overload disease and cancer","volume":"57","author":"Kalinowski","year":"2005","journal-title":"Pharmacol Rev"},{"key":"10.1016\/j.spen.2006.08.008_bib96","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/S0925-4439(01)00041-2","article-title":"Development of potential iron chelators for the treatment of Friedreich\u2019s ataxia: Ligands that mobilize mitochondrial iron","volume":"1536","author":"Richardson","year":"2001","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.spen.2006.08.008_bib97","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1002\/med.1027","article-title":"Design of clinically useful iron(III)-selective chelators","volume":"22","author":"Liu","year":"2002","journal-title":"Med Res Rev"},{"key":"10.1016\/j.spen.2006.08.008_bib98","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/0304-4165(73)90019-6","article-title":"Facilitation of Fe(II) autoxidation by Fe(3) complexing agents","volume":"329","author":"Harris","year":"1973","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.spen.2006.08.008_bib99","first-page":"691","article-title":"Iron chelators for clinical use","volume":"vol 35","author":"Tillbrook","year":"1998"},{"key":"10.1016\/j.spen.2006.08.008_bib100","first-page":"35A","article-title":"Importance of probe molecular geometry in determining intestinal permeability","volume":"2","author":"Hollander","year":"1988","journal-title":"Can J Gastroenterol"},{"key":"10.1016\/j.spen.2006.08.008_bib101","doi-asserted-by":"crossref","first-page":"813","DOI":"10.3181\/00379727-147-38444","article-title":"Lipid solubility and drug penetration of the blood brain barrier","volume":"147","author":"Oldendorf","year":"1974","journal-title":"Proc Soc Exp Biol Med"},{"key":"10.1016\/j.spen.2006.08.008_bib102","first-page":"71","article-title":"Lactulose, 51Cr-labelled ethylenediaminetetra-acetate","volume":"71","author":"Maxton","year":"1986","journal-title":"L-rhamnose and polyethyleneglycol 400 [corrected] as probe markers for assessment in vivo of human intestinal permeability Clin Sci (Lond)"},{"key":"10.1016\/j.spen.2006.08.008_bib103","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/S0020-1693(00)80471-5","article-title":"Iron chelators of the pyridoxal isonicotinoyl hydrazone class. Part I. Ionization characteristics of the ligands and their relevance to biological properties","volume":"170","author":"Richardson","year":"1990","journal-title":"Inorg Chim Acta"},{"key":"10.1016\/j.spen.2006.08.008_bib104","series-title":"Physicochemical principles of pharmacy","author":"Florence","year":"1988"},{"key":"10.1016\/j.spen.2006.08.008_bib105","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1097\/01.moh.0000152631.63469.07","article-title":"New developments in iron chelators","volume":"12","author":"Cunningham","year":"2005","journal-title":"Curr Opin Hematol"},{"key":"10.1016\/j.spen.2006.08.008_bib106","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1182\/blood.V89.3.739","article-title":"Iron-chelating therapy and the treatment of thalassemia","volume":"89","author":"Olivieri","year":"1997","journal-title":"Blood"},{"key":"10.1016\/j.spen.2006.08.008_bib107","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/S0020-1693(02)01040-X","article-title":"Evaluation of new iron chelators and their therapeutic potential","volume":"339","author":"Aouad","year":"2002","journal-title":"Inorg Chim Acta"},{"key":"10.1016\/j.spen.2006.08.008_bib108","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.bbadis.2004.09.001","article-title":"PCTH: A novel orally active chelator of the aroylhydrazone class that induces iron excretion from mice","volume":"1739","author":"Wong","year":"2004","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.spen.2006.08.008_bib109","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1111\/j.1471-4159.1991.tb11444.x","article-title":"The iron chelator desferrioxamine (Desferal) retards 6-hydroxydopamine-induced degeneration of nigrostriatal dopamine neurons","volume":"56","author":"Ben-Shachar","year":"1991","journal-title":"J Neurochem"},{"key":"10.1016\/j.spen.2006.08.008_bib110","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1007\/BF01277665","article-title":"Desferrioxamine and vitamin E protect against iron and MPTP-induced neurodegeneration in mice","volume":"104","author":"Lan","year":"1997","journal-title":"J Neural Transm"},{"key":"10.1016\/j.spen.2006.08.008_bib111","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.2174\/0929867033457584","article-title":"Hydroxyquinolines as iron chelators","volume":"10","author":"Pierre","year":"2003","journal-title":"Curr Med Chem"},{"key":"10.1016\/j.spen.2006.08.008_bib112","series-title":"Critical Stability Constants","author":"Martell","year":"1977"},{"key":"10.1016\/j.spen.2006.08.008_bib113","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1002\/cbf.290090406","article-title":"The effect of ligands on the uptake of iron by cells in culture","volume":"9","author":"Jonas","year":"1991","journal-title":"Cell Biochem Funct"},{"key":"10.1016\/j.spen.2006.08.008_bib114","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/0165-0270(87)90042-2","article-title":"A quinoline fluorescence method for visualizing and assaying the histochemically reactive zinc (bouton zinc) in the brain","volume":"20","author":"Frederickson","year":"1987","journal-title":"J Neurosci Methods"},{"key":"10.1016\/j.spen.2006.08.008_bib115","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/S0896-6273(01)00317-8","article-title":"Treatment with a copper-zinc chelator markedly and rapidly inhibits beta-amyloid accumulation in Alzheimer\u2019s disease transgenic mice","volume":"30","author":"Cherny","year":"2001","journal-title":"Neuron"},{"key":"10.1016\/j.spen.2006.08.008_bib116","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1111\/j.1399-3011.2005.00289.x","article-title":"Synthesis and evaluation of peptidic metal chelators for neuroprotection in neurodegenerative diseases","volume":"66","author":"Zheng","year":"2005","journal-title":"J Pept Res"},{"key":"10.1016\/j.spen.2006.08.008_bib117","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1016\/S0197-4580(02)00120-3","article-title":"Metal complexing agents as therapies for Alzheimer\u2019s disease","volume":"23","author":"Bush","year":"2002","journal-title":"Neurobiol Aging"},{"issue":"Suppl","key":"10.1016\/j.spen.2006.08.008_bib118","first-page":"101","article-title":"The neuropathology of subacute myelo-optico-neuropathy, \u201cSMON\u201d, in the humans: With special reference to the quinoform intoxication","volume":"28","author":"Shiraki","year":"1975","journal-title":"Jpn J Med Sci Biol"},{"key":"10.1016\/j.spen.2006.08.008_bib119","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/S0022-510X(99)00297-X","article-title":"Changes in uptake of vitamin B(12) and trace metals in brains of mice treated with clioquinol","volume":"173","author":"Yassin","year":"2000","journal-title":"J Neurol Sci"},{"key":"10.1016\/j.spen.2006.08.008_bib120","article-title":"Clioquinol for the treatment of Alzheimer\u2019s Disease","volume":"1","author":"Jenagaratnam","year":"2006"},{"key":"10.1016\/j.spen.2006.08.008_bib121","doi-asserted-by":"crossref","first-page":"11840","DOI":"10.1073\/pnas.0502177102","article-title":"Clioquinol down-regulates mutant huntingtin expression in vitro and mitigates pathology in a Huntington\u2019s disease mouse model","volume":"102","author":"Nguyen","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.spen.2006.08.008_bib122","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1001\/archneur.60.12.1685","article-title":"Metal-protein attenuation with iodochlorhydroxyquin (clioquinol) targeting Abeta amyloid deposition and toxicity in Alzheimer disease: A pilot phase 2 clinical trial","volume":"60","author":"Ritchie","year":"2003","journal-title":"Arch Neurol"},{"key":"10.1016\/j.spen.2006.08.008_bib123","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1046\/j.1471-4159.2000.0751219.x","article-title":"Characterization of copper interactions with alzheimer amyloid beta peptides: Identification of an attomolar-affinity copper binding site on amyloid beta1-42","volume":"75","author":"Atwood","year":"2000","journal-title":"J Neurochem"},{"key":"10.1016\/j.spen.2006.08.008_bib124","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/0014-5793(79)80111-8","article-title":"Mobilization of iron from reticulocytes. Identification of pyridoxal isonicotinoyl hydrazone as a new iron chelating agent","volume":"97","author":"Ponka","year":"1979","journal-title":"FEBS Lett"},{"key":"10.1016\/j.spen.2006.08.008_bib125","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1111\/j.1365-2141.1979.tb03771.x","article-title":"Effective iron chelation following oral administration of an isoniazid-pyridoxal hydrazone","volume":"43","author":"Hoy","year":"1979","journal-title":"Br J Haematol"},{"key":"10.1016\/j.spen.2006.08.008_bib126","first-page":"112","article-title":"Pyridoxal isonicotinoyl hydrazone: An effective iron-chelator after oral administration","volume":"27","author":"Brittenham","year":"1990","journal-title":"Semin Hematol"},{"key":"10.1016\/j.spen.2006.08.008_bib127","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1007\/BF01142555","article-title":"Iron chelators of the pyridoxal isonicotinoyl hydrazone class. III. Formation constants with calcium(II), magnesium(II) and zinc(II)","volume":"2","author":"Richardson","year":"1989","journal-title":"Biol Met"},{"key":"10.1016\/j.spen.2006.08.008_bib128","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/S0020-1693(00)80471-5","article-title":"Iron chelators of the pyridoxal isonicotinoyl hydrazone class. Part I. Ionisation characteristics of the ligand and their relevance to biological properties","volume":"170","author":"Richardson","year":"1990","journal-title":"Inorg Chim Acta"},{"key":"10.1016\/j.spen.2006.08.008_bib129","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1139\/y94-093","article-title":"Iron chelators of the pyridoxal isonicotinoyl hydrazone class. Relationship of the lipophilicity of the apochelator to its ability to mobilise iron from reticulocytes in vitro","volume":"72","author":"Ponka","year":"1994","journal-title":"Can J Physiol Pharmacol"},{"key":"10.1016\/j.spen.2006.08.008_bib130","first-page":"399","article-title":"An in vivo evaluation of iron-chelating drugs derived from pyridoxal and its analogs","volume":"221","author":"Johnson","year":"1982","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.spen.2006.08.008_bib131","doi-asserted-by":"crossref","first-page":"4295","DOI":"10.1182\/blood.V86.11.4295.bloodjournal86114295","article-title":"The potential of iron chelators of the pyridoxal isonicotinoyl hydrazone class as effective antiproliferative agents","volume":"86","author":"Richardson","year":"1995","journal-title":"Blood"},{"key":"10.1016\/j.spen.2006.08.008_bib132","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1016\/S0022-2143(99)90173-7","article-title":"Development of novel aroylhydrazone ligands for iron chelation therapy: 2-pyridylcarboxaldehyde isonicotinoyl hydrazone analogs","volume":"134","author":"Becker","year":"1999","journal-title":"J Lab Clin Med"},{"key":"10.1016\/j.spen.2006.08.008_bib133","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/S0022-2143(98)90180-9","article-title":"Pyridoxal isonicotinoyl hydrazone and its analogs: potential orally effective iron-chelating agents for the treatment of iron overload disease","volume":"131","author":"Richardson","year":"1998","journal-title":"J Lab Clin Med"},{"key":"10.1016\/j.spen.2006.08.008_bib134","first-page":"2102","article-title":"The biologically active iron chelators 2- pyridylcarboxaldehyde isonicotinoyl hydrazone, 2-pyridylcarboxaldehyde benzoyl hydrazone and 2-furfural isonicotinoyl hydrazone","volume":"C55","author":"Richardson","year":"1999","journal-title":"Acta Crystallographica Section C"},{"key":"10.1016\/j.spen.2006.08.008_bib135","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1007\/s007750100258","article-title":"Unprecedented oxidation of a biologically active aroylhydrazone chelator catalysed by iron(III): Serendipitous identification of diacylhydrazine ligands with high iron chelation efficacy","volume":"6","author":"Bernhardt","year":"2001","journal-title":"J Biol Inorg Chem"},{"key":"10.1016\/j.spen.2006.08.008_bib136","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1517\/13543784.12.2.235","article-title":"Friedreich\u2019s ataxia: Iron chelators that target the mitochondrion as a therapeutic strategy?","volume":"12","author":"Richardson","year":"2003","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.spen.2006.08.008_bib137","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/0014-5793(94)01111-7","article-title":"A genetic approach to elucidating eukaryotic iron metabolism","volume":"355","author":"Klausner","year":"1994","journal-title":"FEBS Lett"},{"key":"10.1016\/j.spen.2006.08.008_bib138","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1042\/0264-6021:3510477","article-title":"The Fe(II) permease Fet4p functions as a low affinity copper transporter and supports normal copper trafficking in Saccharomyces cerevisiae","volume":"351","author":"Hassett","year":"2000","journal-title":"Biochem J"}],"container-title":["Seminars in Pediatric Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1071909106001070?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1071909106001070?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,8,4]],"date-time":"2021-08-04T18:52:22Z","timestamp":1628103142000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1071909106001070"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,9]]},"references-count":138,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2006,9]]}},"alternative-id":["S1071909106001070"],"URL":"https:\/\/doi.org\/10.1016\/j.spen.2006.08.008","relation":{},"ISSN":["1071-9091"],"issn-type":[{"value":"1071-9091","type":"print"}],"subject":[],"published":{"date-parts":[[2006,9]]}}}